Oncology Drug Spending By Health Plans May Rise 50% By 2010 – Medco
Long-term cancer treatment with targeted oral therapies will spur a 46 percent to 53 percent surge in health plan spending on oncology drugs within the next three years, Medco predicts in its 2008 Drug Trend Report (see chart: "1Drug Spending By Health Plans: 2008-2010 Forecast")
You may also be interested in...
OTC entries drive Rx utilization down.
WellCare anticipates a net loss in the first quarter 2008, versus net income of $25 million in the first quarter of 2007, due to higher medical expenses and costs associated with ongoing government and special committee investigations
GlaxoSmithKline's idiopathic thrombocytopenic purpura therapy Promacta will undergo a review by FDA's Oncologic Drugs Advisory Committee May 30. GSK is seeking approval for short-term, second-line use of Promacta (eltrombopag) to increase platelet counts and reduce or prevent bleeding in patients with chronic ITP. The company plans to follow up with a broader application for chronic ITP this year. Amgen's platelet producer Nplate (romiplostim) recently received ODAC support, but a major amendment has since delayed the application (1"The Pink Sheet," March 17, 2008, p. 3)...